Novartis AG ADR

AI Summary

Novartis develops and sells prescription medicines across cardiovascular disease (Entresto for heart failure), immunology (Cosentyx for psoriasis and arthritis), oncology (Pluvicto for prostate cancer, Kisqali for breast cancer), and rare diseases (Zolgensma for spinal muscular atrophy) [Yahoo Finance]. The company operates globally, manufacturing drugs in multiple countries and selling through hospitals, clinics, and specialty pharmacies [Yahoo Finance].

Novartis is a Swiss pharmaceutical giant with over 75,000 employees making drugs for heart disease, cancer, immune disorders, and rare genetic conditions [Yahoo Finance]. The company posted $54.8B in revenue with strong margins (75% gross, 32% operating) and solid cash generation ($17.7B free cash flow), reflecting a diversified portfolio of branded medicines [Yahoo Finance]. Recent positive clinical trial results for Pluvicto, a radioactive cancer therapy, have driven modest stock gains and positioned Novartis as a leader in an emerging treatment category [Simply Wall St].

Novartis is financially healthy with strong profitability, low leverage, and consistent cash generation [Yahoo Finance].

Recent News

• Novartis (SWX:NOVN) Valuation Check After New Pluvicto PSMAddition Study Data And Regulatory Filings

  Simply Wall St· 2026-05-20

• Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion

  Yahoo Finance· 2026-05-18

• Novartis' Pluvicto Shows Lower Risk Of PSA Progression In Phase 3 PSMAddition Trial For MHSPC

  Nasdaq· 2026-05-18

• Novartis Expands US Radioligand Network And Manufacturing For Future Growth

  Simply Wall St· 2026-05-14

• New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

  Yahoo Finance· 2026-05-17

• Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Antagonists and Inhibitors by Drug Modality

  Yahoo Finance· 2026-05-14